{
  "kind": "treatment",
  "slug": "agomelatine-valdoxan",
  "type": "antidepressant",
  "name": "Agomelatine (Valdoxan)",
  "summary": "An atypical antidepressant with melatonergic agonist and serotonergic antagonist activity, used for major depressive disorder.",
  "description": "Agomelatine is a novel antidepressant that acts as an agonist at melatonin MT1 and MT2 receptors and as an antagonist at serotonin 5-HT2C receptors. It is approved in several countries for the treatment of major depressive disorder (MDD) in adults. It may improve sleep quality while exerting antidepressant effects.",
  "category": "medications/antidepressants",
  "tags": [
    "atypical-antidepressant",
    "melatonin-agonist",
    "5ht2c-antagonist",
    "depression"
  ],
  "metadata": {
    "drug_classes": [
      "Melatonergic Antidepressant",
      "Atypical Antidepressant"
    ],
    "therapeutic_categories": [
      "Depression",
      "Mood Disorders"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": false,
    "brand_names": [
      "Valdoxan",
      "Thymanax"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Adult"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Primary Care"
    ],
    "fda_approval_year": 2009
  },
  "clinical_metadata": {
    "primary_indications": [
      "Depression"
    ],
    "off_label_uses": [
      "Generalized Anxiety Disorder",
      "Seasonal Affective Disorder"
    ],
    "contraindications": [
      "Hepatic impairment",
      "Concurrent use with potent CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin)"
    ],
    "monitoring_required": [
      "Liver function tests before initiation and periodically during treatment"
    ],
    "efficacy_rating": {
      "depression": 3,
      "overall_tolerability": 4
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "agomelatine",
      "valdoxan",
      "melatonin agonist antidepressant"
    ],
    "synonyms": [
      "agomelatine hydrochloride"
    ],
    "common_misspellings": [
      "agomelatin",
      "valdaxon"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Major Depressive Disorder (MDD)"
      ]
    },
    {
      "type": "mechanism",
      "text": "Agonist at MT1 and MT2 melatonin receptors, helping regulate circadian rhythms, and antagonist at 5-HT2C serotonin receptors, enhancing norepinephrine and dopamine release in the frontal cortex."
    },
    {
      "type": "dosing",
      "adult": {
        "start": "25 mg once daily at bedtime",
        "titrate": "May increase to 50 mg daily after 2 weeks if no improvement",
        "max": "50 mg/day"
      },
      "geriatric": "Use with caution; monitor liver function closely",
      "hepatic_impairment": "Contraindicated",
      "renal_impairment": "No adjustment generally needed; caution in severe impairment"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 25 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Antidepressant effects may be observed within 1–2 weeks, with full response potentially taking 4–6 weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "headache",
        "dizziness",
        "somnolence",
        "nausea",
        "diarrhea",
        "anxiety"
      ],
      "less_common": [
        "insomnia",
        "abdominal pain",
        "weight gain"
      ],
      "serious": [
        "hepatotoxicity",
        "suicidal ideation"
      ]
    },
    {
      "type": "warnings",
      "black_box": null,
      "other": [
        "Monitor liver function before initiation, at weeks 3, 6, 12, and 24, and when clinically indicated",
        "Discontinue if transaminases exceed 3× ULN"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Potent CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin)",
          "risk": "↑ agomelatine levels, risk of hepatotoxicity",
          "action": "Contraindicated"
        },
        {
          "with": "Alcohol",
          "risk": "Increased liver toxicity",
          "action": "Avoid"
        },
        {
          "with": "Other hepatotoxic drugs",
          "risk": "Additive hepatotoxicity",
          "action": "Use caution"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Liver function tests (baseline, weeks 3, 6, 12, and 24, and when clinically indicated)",
        "Mood/suicidality",
        "Sleep patterns and quality"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use if benefits outweigh risks; data limited.",
      "lactation": "Unknown excretion; use caution.",
      "pediatrics": "Not established; not recommended.",
      "geriatrics": "Monitor liver closely; use lower doses if possible."
    },
    {
      "type": "tapering",
      "text": "No significant withdrawal symptoms reported; tapering usually not necessary but may be considered."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Particularly useful when depression is accompanied by sleep disturbance and circadian rhythm disruption.",
        "No significant sexual side effects compared to SSRIs/SNRIs.",
        "Should not be used in patients with active liver disease or elevated transaminases."
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "EMA Product Information",
          "url": "https://www.ema.europa.eu/"
        },
        {
          "label": "NICE Guidance on Depression",
          "url": "https://www.nice.org.uk/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Agomelatine (Valdoxan): Dosing, Side Effects, Interactions",
    "description": "Comprehensive guide to agomelatine for depression, including dosing, safety, and monitoring recommendations."
  }
}
